Other Scholarly Content
 

FurunoJonPharmacyNationwideAnalysisAntibiotic.pdf

Pubblico Deposited

Contenuto scaricabile

Scarica il pdf
https://ir.library.oregonstate.edu/concern/defaults/fq977v61w

Descriptions

Attribute NameValues
Creator
Abstract
  • Context: Antibiotic prescribing in hospice patients is complicated by the focus on palliative rather than curative care and concerns regarding increasing antibiotic resistance. Objective: To estimate antibiotic use in a national sample of hospice patients and identify facility and patient characteristics associated with antibiotic use in this population. Methods: This was an analysis of data from the 2007 National Home and Hospice Care Survey, a nationally-representative sample of U.S. hospice agencies. We included data from 3,884 patients who died in hospice care. Our primary outcome measure was prevalence of antibiotic use in the last 7 days of life. Diagnoses, including potential infectious indications for antibiotic use, were defined using International Classification of Diseases, Ninth Revision (ICD-9) codes. Chi-square tests and t-tests were used to quantify associations of patient and facility characteristics with antibiotic use. Results: During the last 7 days of life, 27% (95% confidence interval (CI); 24%, 30%) of patients received at least one antibiotic and 1.3% (95% CI; 0.7%, 2.0%) received ≥ 3 antibiotics. Among patients who received at least one antibiotic, 15% (95% CI; 10%, 20%) had a documented infectious diagnosis, compared with 9% (95% CI; 7%, 11%) who had an infectious diagnosis but received no antibiotics. Conclusions: In this nationally-representative sample, 27% of hospice patients received an antibiotic during the last 7 days of life, most without a documented infectious diagnosis. Further research is needed to elucidate the role of antibiotics in this patient population to maintain palliative care goals while reducing unnecessary antibiotic use.
Dichiarazione dei diritti

Le relazioni

Parents:

Elementi

Thumbnail Titolo Data caricata Visibilità Azioni
file details FurunoJonPharmacyNationwideAnalysisAntibiotic.pdf 2017-07-14 Pubblico Scaricare